Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figure Technology Solutions Inc. Class A Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $25 (market cap $6.11B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Figure Technology Solutions Inc. Class A Common Stock is far larger — about 6.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FIGR | MRVI | |
|---|---|---|
Market Cap | $6.11B | $972.90M |
Volume | 5,025,604 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $73.91 | $9.00 |
52-Week Low | $24.91 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $6.15B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGR trades at $27.25, down 4.25% over 24 hours, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS beat expectations at $0.37, revenue grew to $509.30M in 2025, and net income margin improved to 33.83% in 2026. Recent news highlights the Kiavi acquisition and partnership with Sierra to enhance AI-driven lending capabilities, supporting growth in loan volumes.
Wall Street maintains a bullish outlook with a consensus price target of $50.00, implying significant upside. However, risks include recent earnings misses in Q4 2025 and Q1 2026, negative operating cash flow projected for 2026, and competitive pressures in the lending infrastructure space. The stock's high P/E of 28.52 warrants caution amid growth execution uncertainties.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figure Technology Solutions Inc. Class A Common Stock
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
